Major API trade encountermultiple sandals or long-term decline

With the transfer of the global API industry in the 1990s, China has developed into the world's largest producer and exporter of chemical RAW Materials and Pharmaceuticals, driven by high pollution and high energy consumption in exchange for low cost, and serious overcapacity has led to frequent price warsAmong them, penicillin, vitamin C accounted for more than 50% of the international market shareUPn
The trade of bulk API encountered multiple difficulties or long-term decline
UPnpublic information shows that the development of China's traditional bulk API series, vitamin series and decoheat analgesics-basedDue to the low technical threshold, a large number of competitors join the bulk of chemical APIUPn
Xu Ming, vice president of china's Medical and Health Products Import and Export Chamber of Commerce, told the Daily Economic News that China's traditional bulk API trade has encountered multiple difficulties and will be in the downward channel for a long timeUPn
The heavy overcapacity in the bulk API industry, coupled with lower export demand, the impact of the country's "limited resistance" policy on demand for antibiotics, coupled with low-cost competition from developing countries such as India and Mexico, must transform API manufacturersUPn
In addition, API in recent years also frequently encountered in the international market "double anti" investigation "The price is high, it's anti-monopoly, it's low, it's anti-dumping." Over the past few years, there has been an increase in international trade investigations into Chinese API Xu Ming ru told the Daily Economic News UPn
　　According to the latest data released by the Ministry of Industry and Information Technology, China's total profit from the manufacture of chemical raw materials last year was 28.47 billion yuan, with a profit margin of 7.45 percent, up 0.02 percent year-on-year, and the industry average was 10.13 percent Shanghai Securities analysts believe that because the overall supply and demand situation of the industry has not changed significantly, the earnings outlook of the API industry is still poor in terms of the current revenue and profit growth of listed companies UPn
　　Zhejiang Pharma's net profit fell 46.72 percent year-on-year last year, driven by weak market demand for vitamin E, the leading product, and intense competition The downward export is only the surface of the downturn of the bulk API industry, and adjusting the industrial structure is a more critical issue Bulk API belongs to the extensive type of low value-added products, the current state encourages the upgrading of API is the intermediate production enterprises to the field of API transfer, bulk API to the specialised API transfer, the characteristic api to the preparation transfer UPn with the transfer of the global API industry in the 1990s, in the high pollution, high energy consumption in exchange for low-cost promotion, China has developed into the world's largest producer and exporter of chemical raw materials and pharmaceuticals, serious overcapacity led to frequent price wars Among them, penicillin, vitamin C accounted for more than 50% of the international market share UPn
　　The trade of bulk API encountered multiple difficulties or long-term decline
UPn public information shows that the development of China's traditional bulk API series, vitamin series and decoheat analgesics-based Due to the low technical threshold, a large number of competitors join the bulk of chemical API UPn
　　Xu Ming, vice president of china's Medical and Health Products Import and Export Chamber of Commerce, told the Daily Economic News that China's traditional bulk API trade has encountered multiple difficulties and will be in the downward channel for a long time UPn
　　The heavy overcapacity in the bulk API industry, coupled with lower export demand, the impact of the country's "limited resistance" policy on demand for antibiotics, coupled with low-cost competition from developing countries such as India and Mexico, must transform API manufacturers UPn
　　In addition, API in recent years also frequently encountered in the international market "double anti" investigation "The price is high, it's anti-monopoly, it's low, it's anti-dumping." Over the past few years, there has been an increase in international trade investigations into Chinese API Xu Ming ru told the Daily Economic News UPn
　　According to the latest data released by the Ministry of Industry and Information Technology, China's total profit from the manufacture of chemical raw materials last year was 28.47 billion yuan, with a profit margin of 7.45 percent, up 0.02 percent year-on-year, and the industry average was 10.13 percent Shanghai Securities analysts believe that because the overall supply and demand situation of the industry has not changed significantly, the earnings outlook of the API industry is still poor in terms of the current revenue and profit growth of listed companies UPn
　　Zhejiang Pharma's net profit fell 46.72 percent year-on-year last year, driven by weak market demand for vitamin E, the leading product, and intense competition The downward export is only the surface of the downturn of the bulk API industry, and adjusting the industrial structure is a more critical issue Bulk API belongs to the extensive type of low value-added products, the current state encourages the upgrading of API is the intermediate production enterprises to the field of API transfer, bulk API to the specialised API transfer, the characteristic api to the preparation transfer UPn